1. Home
  2. TBPH vs NDMO Comparison

TBPH vs NDMO Comparison

Compare TBPH & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • NDMO
  • Stock Information
  • Founded
  • TBPH 2013
  • NDMO 2019
  • Country
  • TBPH United States
  • NDMO United States
  • Employees
  • TBPH N/A
  • NDMO N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • NDMO Trusts Except Educational Religious and Charitable
  • Sector
  • TBPH Health Care
  • NDMO Finance
  • Exchange
  • TBPH Nasdaq
  • NDMO Nasdaq
  • Market Cap
  • TBPH 699.0M
  • NDMO 620.6M
  • IPO Year
  • TBPH N/A
  • NDMO N/A
  • Fundamental
  • Price
  • TBPH $14.58
  • NDMO $10.41
  • Analyst Decision
  • TBPH Strong Buy
  • NDMO
  • Analyst Count
  • TBPH 4
  • NDMO 0
  • Target Price
  • TBPH $23.00
  • NDMO N/A
  • AVG Volume (30 Days)
  • TBPH 367.5K
  • NDMO 218.6K
  • Earning Date
  • TBPH 11-11-2025
  • NDMO 01-01-0001
  • Dividend Yield
  • TBPH N/A
  • NDMO 6.75%
  • EPS Growth
  • TBPH N/A
  • NDMO N/A
  • EPS
  • TBPH 0.26
  • NDMO N/A
  • Revenue
  • TBPH $77,205,000.00
  • NDMO N/A
  • Revenue This Year
  • TBPH $79.82
  • NDMO N/A
  • Revenue Next Year
  • TBPH N/A
  • NDMO N/A
  • P/E Ratio
  • TBPH $56.32
  • NDMO N/A
  • Revenue Growth
  • TBPH 24.49
  • NDMO N/A
  • 52 Week Low
  • TBPH $7.88
  • NDMO $8.99
  • 52 Week High
  • TBPH $15.15
  • NDMO $11.24
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 60.51
  • NDMO 58.95
  • Support Level
  • TBPH $14.00
  • NDMO $10.31
  • Resistance Level
  • TBPH $14.87
  • NDMO $10.50
  • Average True Range (ATR)
  • TBPH 0.50
  • NDMO 0.11
  • MACD
  • TBPH -0.02
  • NDMO -0.02
  • Stochastic Oscillator
  • TBPH 62.00
  • NDMO 54.17

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest

Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.

Share on Social Networks: